D/C/F/TAF + DRV + COBI + FTC/TDF + D/C/F/TAF Placebo + DRV Placebo + COBI Placebo + FTC/TDF Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acquired Immunodeficiency Syndrome
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Trial Timeline
Apr 1, 2012 → Feb 1, 2014
NCT ID
NCT01565850About D/C/F/TAF + DRV + COBI + FTC/TDF + D/C/F/TAF Placebo + DRV Placebo + COBI Placebo + FTC/TDF Placebo
D/C/F/TAF + DRV + COBI + FTC/TDF + D/C/F/TAF Placebo + DRV Placebo + COBI Placebo + FTC/TDF Placebo is a phase 2 stage product being developed by Gilead Sciences for Acquired Immunodeficiency Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01565850. Target conditions include Acquired Immunodeficiency Syndrome, HIV Infections.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01565850 | Phase 2 | Completed |
Competing Products
20 competing products in Acquired Immunodeficiency Syndrome